Summary of Clinical Use

Mepolizumab is approved for the treatment of severe asthma in patients who are already taking other asthma medications [2,8]. In the United States and the European Union, mepolizumab can be used under orphan drug designation for the treatment of Churg-Strauss syndrome and hypereosinophilic syndrome. Click here to link to ClinicalTrials.gov's full list of mepolizumab trials, including ongoing trials in additional eosinophilic conditions.

Mechanism Of Action and Pharmacodynamic Effects

Mepolizumab antagonises IL-5 activity by effectively neutralising circulating IL-5. This leads to a reduction in eosinophil numbers in blood, tissue and sputum [3,7] and this effect underlies the drug's anti-inflammatory action [6,9].

External links

For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)